Expanding the immunosuppresive repertoire
Nancy L. Ascher – 1 July 1996 – In a 6 month open label, randomized, multi‐center trial, we compared the efficacy and safety of mycophenolate mofetil (MMF) with high dose intravenous steroids (IVS) for the treatment of refractory, acute cellular rejection in recipients of first or second cadaveric or living‐donor renal allografts. A total of 150 patients were enrolled and randomized in a 1‐to‐1 ratio to receive oral MMF 1.5 g twice daily (n = 77) or i.v.